Authors' recommendations: After considering the strength of the available evidence in relation to the safety, clinical effectiveness and cost-effectiveness of the injection of botulinum toxin in the treatment of urinary incontinence related to neurogenic detrusor overactivity, MSAC deferred the application until its responses to PBAC's requests, its other advice, and further information from the applicant, are considered by PBAC. If PBAC refers more matters to MSAC for advice, or the applicant has reason to disagree with the advice given above, MSAC will support an expedited process for reconsideration. If PBAC subsequently decides to recommend to the Minister that botulinum toxin be listed on the PBS for the treatment of urinary incontinence related to neurogenic detrusor overactivity, MSAC will support an expedited process for reconsideration, to align MSAC support for public funding of the injection of botulinum toxin according to the circumstances recommended by PBAC. The purpose of this reconsideration would be to align the proposed MBS item descriptor with the proposed PBS restriction; consider the exclusion of other items to be billed to the patient on the same occasion of service; and consider changes in the estimates of costs to the MBS. MSAC also advised the Minister that the current MBS item 36581 should be rewritten to exclude its use for injecting botulinum toxin at a time considered reasonable.

Project Status: Completed

Year Published: 2012

URL for published report: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1221-public

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Australia

Organisation Name: Medical Services Advisory Committee

Contact Address: MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.

Contact Name: msac.secretariat@health.gov.au

Contact Email: msac.secretariat@health.gov.au

Copyright: Medical Services Advisory Committee (MSAC)